MBRX
Moleculin Biotech, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.71
+5.09%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.2x
Market Cap
$13.83M
MomentumView details →
1D Return
+5.09%
YTD Return
−77.96%
RSI (14)
42.0
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.2x
Market Cap
$13.83M
RSI (14)
42.0
MomentumView details →
1D Return
+5.09%
YTD Return
−77.96%
SummaryUpdated Jun 1, 2026
Moleculin Biotech, Inc. (NASDAQ:MBRX) is a clinical-stage pharmaceutical company founded in 2015 and headquartered in Houston, Texas. The company went public in June 2016 and focuses on developing innovative drug candidates specifically designed to treat highly resistant tumors and viruses. Moleculin operates in the biotechnology sector within the broader healthcare industry, positioning itself as a specialized developer of oncology therapeutics with a particular emphasis on addressing unmet medical needs in cancer treatment where existing therapies have failed or proven inadequate.
Similar companies
Latest newsMore news →
Moleculin Biotech reported financial results for the second quarter ended June 30, 2026, and highlighted progress in its pivotal MIRACLE trial for Annamycin in relapsed/refractory AML.22d agoMoleculin Biotech priced a best-efforts public offering of 12,376,667 shares of common stock (or pre-funded warrants in lieu thereof) and warrants to purchase up to 37,130,001 shares at a combined price of $0.75 per share, expected to close on or about August 3, 2026.36d agoMoleculin Biotech reported positive interim data from its MIRACLE R/R AML trial, showing a blinded CRc of 37% in venetoclax-failed patients, with enrollment at 74 of 90 patients and final Part A treatment expected in September 2026.36d ago